Etripamil is under clinical development by Milestone Pharmaceuticals and currently in Phase III for Supraventricular Tachycardia. According to GlobalData, Phase III drugs for Supraventricular Tachycardia have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Etripamil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Etripamil (MSP-2017) is under development for the treatment of transient cardiovascular conditions such as paroxysmal supraventricular tachycardia (PSVT), and atrial fibrillation. The drug candidate is a short-acting therapeutic administered by intranasal route as a spray. It is a new chemical entity and acts by targeting calcium channel.
It was under development for stable angina.
Milestone Pharmaceuticals overview
Milestone Pharmaceuticals is a Pharmaceutical company. It develops novel small molecule therapeutics. The company undertakes the development of small molecule therapeutics based on clinically validated mechanisms, for the treatment of cardiovascular diseases. The company’s lead product etripamil, is a potent short-acting calcium channel antagonist for the systemic treatment of cardiovascular conditions such as angina, paroxysmal supraventricular tachycardia and atrial arrhythmias. It offers products through nasal sprays for the provision of rapid systemic drug delivery that can be used by electrocardiogram (ECG)-diagnosed patient. It operates in the US and Canada. Milestone Pharmaceuticals is headquartered in Saint-Laurent, Quebec, Canada.
For a complete picture of Etripamil’s drug-specific PTSR and LoA scores, buy the report here.